Genmab (XTRA:GE9) - Stock Price, News & Analysis

GE9 Stock Overview

Develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.

GE9 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 63.5% below our estimate of its fair value

Earnings are forecast to grow 28.92% per year

Risk Analysis

High level of non-cash earnings

Shares are highly illiquid

Profit margins (26.4%) are lower than last year (51.7%)

Genmab A/S Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€770.0m

Sartorius

XTRA:SRT3

€18.1b

Merck KGaA

XTRA:MRK

€72.1b

Price History & Performance

Summary of all time highs, changes and price drops for Genmab
Historical stock prices
Current Share Price	kr.331.00
52 Week High	kr.353.50
52 Week Low	kr.283.00
Beta	0.60
1 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	4,840.30%

Recent updates

Shareholder Returns

	GE9	DE Biotechs	DE Market
7D	0%	0.2%	1.6%
1Y	n/a	-24.4%	7.3%

Return vs Industry: Insufficient data to determine how GE9 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how GE9 performed against the German Market.

Price Volatility

Is GE9's price volatile compared to industry and market?
GE9 volatility
GE9 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.6%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: GE9 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine GE9's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	1,309	Jan van de Winkel	www.genmab.com

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.

Genmab A/S Fundamentals Summary

How do Genmab's earnings and revenue compare to its market cap?
GE9 fundamental statistics
Market cap	€22.80b
Earnings (TTM)	€319.26m
Revenue (TTM)	€1.21b

71.4x

P/E Ratio

18.8x

P/S Ratio

Is GE9 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GE9 income statement (TTM)
Revenue	kr.9.02b
Cost of Revenue	kr.0
Gross Profit	kr.9.02b
Other Expenses	kr.6.64b
Earnings	kr.2.38b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 10, 2022

Earnings per share (EPS)	36.38
Gross Margin	100.00%
Net Profit Margin	26.35%
Debt/Equity Ratio	0%

How did GE9 perform over the long term?

See historical performance and comparison

GE9 Stock Overview

Rewards

Risk Analysis

Genmab A/S Competitors

XTRA:BIO3

€1.4b

XTRA:FYB

€770.0m

XTRA:SRT3

€18.1b

XTRA:MRK

€72.1b

Price History & Performance

Recent News & Updates

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Recent updates

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

High number of new directors

Shareholder Returns

Price Volatility

About the Company

Genmab A/S Fundamentals Summary

71.4x

18.8x

Earnings & Revenue